Kura Oncology Inc. (NASDAQ:KURA) shot up 9.4% during trading on Wednesday . The company traded as high as $4.13 and last traded at $3.61, with a volume of 412,583 shares trading hands. The stock had previously closed at $3.30.

A number of research firms have recently commented on KURA. Citigroup Inc. reduced their price objective on shares of Kura Oncology from $19.00 to $12.00 and set a “buy” rating on the stock in a research note on Monday, March 21st. Zacks Investment Research raised shares of Kura Oncology from a “hold” rating to a “buy” rating and set a $4.75 target price on the stock in a research note on Tuesday, March 22nd. Finally, Oppenheimer Holdings Inc. reissued an “outperform” rating and set a $16.00 target price on shares of Kura Oncology in a research note on Tuesday, June 21st.

The stock has a 50-day moving average of $2.89 and a 200 day moving average of $3.96. The company’s market cap is $67.31 million.

Kura Oncology (NASDAQ:KURA) last posted its quarterly earnings results on Wednesday, May 11th. The company reported ($0.36) EPS for the quarter, missing the consensus estimate of ($0.35) by $0.01. On average, equities research analysts predict that Kura Oncology Inc. will post ($1.70) EPS for the current year.

Kura Oncology, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in discovering and developing personalized therapeutics for the treatment of solid tumors and blood cancers. Its segment is engaged in the discovery and development of personalized therapeutics for the treatment of solid tumors and blood cancers.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.